Ulyee Choe, DO
Fellowship, Infectious Disease, University of South Florida, Tampa, FL
Residency, Internal Medicine, University of South Florida, Tampa, FL
Rotating Internship, Northside Hospital, St. Petersburg, FL
DO, Nova Southeastern University College of Osteopathic Medicine, Ft. Lauderdale, Fl
Phone: (813) 844-4187
Dr. Choe received his DO from Nova Southeastern University in Ft. Lauderdale, Florida. He completed his residency in Internal Medicine and his fellowship in Infectious Disease and International Medicine at the University of South Florida. After completing his ID fellowship in 2011, Dr. Choe accepted the position of Assistant Professor of Medicine with the Division of Infectious Disease and International Medicine at USF. In November 2012, Dr. Choe was named Interim Director of the Polk County Health Department.
Dr. Choe is a member of the Institutional Biosafety Committee at USF and recently developed a Laboratory Exposure Protocol for USF clinicians. He is a diplomate of both the American Board of Internal Medicine and the American Board of Internal Medicine - Infectious Disease. He is an active member of the Infectious Disease Society of America and the Florida Infectious Disease Society. Dr. Choe is an International Liaison and Preceptor for USF Medicine International's medical observership program with Yeungnam Medical School in South Korea.
Areas of Expertise
HIV, Laboratory Biosafety and Exposure
Current Research (Co-Investigator)
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-bosted Atazanavir versus Ritonavir-Boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Ritonavir-boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults.
A Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS 9137 (GS 9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of HIV-1 Infected subjects.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination with Optimized Background Therapy versus Optimized Background Therapy along for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects. [Pfizer A4001027]
A Randomized, Controlled, Partially-Blinded Phase IIb Dose-finding Trial of TMC125 in HIV-1 Infected Subjects with Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and with at Least Three Primary PI Mutations. (TMC125-C223)
A Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir versus Lamivudine in Combination with Efavirenz and 4 Tenofovir in HIV-1 Infected, Treatment-Naïve Subjects, with a 12-Week Extension Treatment Period. [ACH443-015]
A Large, Simple Trial Comaring Two Strategies for Management of Anti-Retroviral Therapy. [SMART CPCRA 065]
A Randomized, Controlled, Open-Label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/Ritonavir versus Lopinavir/Ritonavir in Treatment-Naïve HIV-1 Infected Subjects. This trial will be referred to as ARTMEMIS. [TMC114-211]
Choe U, Oller K, Casanas, B. An Unusual Case of Toxoplasmosis Presenting as a Cecal Mass. Awaiting publication.Choe U, Casanas B. Polymicrobial Bacteremia with Eggerthella lenta and Peptostreptococcus micros Associated with a Lung Abscess. Awaiting publication.
Kunadharaju R, Choe U, Harris J, et al. Case report: Cryptococcus Gattii - Emerging fungal pathogen in Florida. Submitted.
Choe U, Nasr G, Shah M, et al. HIV Virologic Outcomes in Associated with Ritonavir-boosted Atazanavir and Concomitant Acid Suppressive Therapy. Poster to be presented at Infectious Disease Society of America, Boston, MA. October 2011. Awarded traveler’s grant.
Carrington M, Choe U, Stanek D, et al. A fatal case of brucellosis misdiagnosed in early stages of B. suis infection in a 46-year-old patient with Marfan syndrome. Poster to be presented at: 64th Brucellosis Research Conference, Buenos Aires, Argentina. September 2011.
Gompf SG, Smith K, Choe U. Arenaviruses. eMedicine at WebMD. 2011. Available online.
Choe U. HPV Vaccine Recommendations. Florida/Caribbean AIDS Education and Training Center HIV Carelink. 2011; 12 (2).
Choe U. HIV Treatment Strategies. Presentation at the HIV Intensive Course at the Southeast STD/HIV Prevention Training Center, Tampa, FL. October 2010.
Choe U. HIV Virologic Outcomes in Associated with Ritonavir-boosted Atazanavir and Concomitant Acid Suppressive Therapy. Presentation at Florida Infectious Disease Society Meeting; Orlando, FL. June 2010.
Franck R, Choe U, Montero J. A case of coccidioidomycosis presenting as military tuberculosis. Poster presented at: The American College of Physicians; Tampa, FL Sept 2007.